期刊文献+

双特异性抗体药物应用进展 被引量:3

Application of Bispecific Antibody Drugs
下载PDF
导出
摘要 基因工程的飞速发展推动了新型双功能抗体药物的成功研制。目前双功能抗体药物主要应用于肿瘤的免疫治疗、自身免疫疾病和感染类疾病的治疗,在组织再生和临床诊断领域也有应用。就双特异性抗体的发展史进行了简要回顾,对其在免疫治疗、组织再生和临床诊断等领域中的应用进展进行了综述,并展望了未来的发展方向,以期为新型双特异性抗体药物的研制提供参考。 Rapid development of gene engineering has led to the success of the new type of bispecific antibody drugs. At present,the application of dual bispecific antibody drugs was in tumor immunotherapy,autoimmune diseases,infectious diseases,tissue regeneration and clinical diagnosis. In this paper,the brief development history was introduced,and applications of bispecific antibodies in immunological therapy,tissue regeneration and clinical diagnosis were reviewed. At last,development prospect was forecasted. The paper was expected to provided reference for the research and development of new bispecific antibody drugs.
出处 《生物技术进展》 2015年第6期420-424,共5页 Current Biotechnology
基金 国家科技重大专项项目(2012ZX09101313) 河北省重大科技成果转化专项(13042404Z)资助
关键词 BiTE(T-细胞的双特异抗体) 双特异性抗体 免疫治疗 组织再生 Bi TE(bispecific T cell engager) bispecific antibodies immunotherapy regenerative medicine
  • 相关文献

参考文献16

  • 1Coloma M J, Morrison S L. Design and production of novel tet- ravalent bispecific antibodies [ J ]. Nat. Biotechnol., 1997, 15 (2) :159-163.
  • 2Nisonoff A, Rivers M M. Recombination of a mixture of univa- lent antibody fragments of different specificity [ J ]. Arch. Bio- chem. Biophys., 1961,93:460-462.
  • 3Zou J, Chen D, Zong Y, et al.. Immunotherapy based on bis- pecific T-cell engager with hIgG1 Fc sequence as a new thera- peutic strategy in multiple myeloma [ J ]. Can. Sci., 2015,106 (5) :512-521.
  • 4Wu X, Sereno A J, Huang F, et al.. Fab-based bispecific an- tibody formats with robust biophysical properties and biological activity[ J]. mAbs,2015,7(3) :470-482.
  • 5Moore G L, Bautista C, Pang E, et al.. A novel bispecific an- tibody format enables simultaneous bivalent and monovalent co- engagement of distinct target antigens [ J ]. mAbs, 2011,3 ( 6 ) : 546-557.
  • 6Kontermann R E. Dual targeting strategies with bispecifie anti- bodies[J], mAbs,2012, 4(2) :182-197.
  • 7Zeng J, Liu R, Wang J, et al.. A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and 14LA-DR[J]. J. Can. Res. Clin. Oncol.,2015,141 (11): 1899-1907.
  • 8Osada T, Pate1 S P, Hammond S A, et al.. CEA/CD3-bispe- cific T cell-engaging (BITE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1[ J]. Can. Immunol. Immunother., 2015,64(6) :677-688.
  • 9Sun L L, Ellerrnan D, Mathieu M, et al.. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies[J]. Sci. Transl. Med. ,2015,7(287) : 270-287.
  • 10Lee R J, Fang Q, Davol P A, et al.. Antibody targeting of stem cells to infarcted myocardium [ J ]. Stem Cells, 2007,25 (3) :712-717.

同被引文献11

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部